Zacks: Merck will benefit from Schering deal

Merck needs the Schering-Plough deal, a new Zacks analyst report states. Schering's still-on-patent drugs will help make up Merck's shortfalls as its branded meds start to face generic competition. Plus, Zacks sees "immediate synergies"--read cost-cutting opportunities--for the two companies' cholesterol drugs partnership. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.